Drug Trial Radar · NCT05944848
A Study of CL-197 Capsules in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Nov 16, 2022
Primary completion
Jan 20, 2024
Study completion Jan 20, 2024
Sponsor
- Lead sponsor
- Henan Genuine Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetic characteristics of CL-197 capsules in health conditions.
Conditions
- HIV-1
Interventions
1 mg CL-197 capsulesDrug
Single oral dose of 1 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
10 mg CL-197 capsules or CL-197 placeboDrug
Single oral dose of 10 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
30 mg CL-197 capsules or CL-197 placeboDrug
Single oral dose of 30 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
60 mg CL-197 capsules or CL-197 placeboDrug
Single oral dose of 60 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
100 mg CL-197 capsules or CL-197 placeboDrug
Single oral dose of 100 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Safety and Tolerability of CL-197 Capsules :Incidence of Treatment-Emergent Adverse Events as Assessed by The NCI CTCAE V5.0 Grading CriteriaTime frame: Up to 29 days post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Fifth Medical Center of Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.